Last updated 8 September 2026 · Originally published 24 January 2023
The difference between CBD and CBDA is time and heat. CBDA is what your CBD used to be: cannabidiolic acid, the form the hemp plant naturally makes. Heat removes part of its molecule and converts it into CBD; ageing and warm storage do the same thing more slowly. For years CBDA was treated as merely unfinished CBD. It is now sold as a product in its own right, on some genuinely interesting science and some claims that run far ahead of it. Here is where the line sits.
What it is, and why “raw” products are unstable
In the living plant, cannabinoids exist mostly as acids: CBDA, THCA and their relatives. Heat converts them to the forms most people know, but so, more slowly, do time, light and warm storage. That means a CBDA product gradually changes during storage: a “raw” extract loses CBDA and gains CBD over time. If you are paying for CBDA, that has two practical consequences. Check the certificate of analysis for a CBDA line with a recent test date, and store it as directed, tightly closed and away from heat and light. A COA also settles what “total CBD” means on a label — the calculation is in that article.
The two things that make CBDA interesting
First, absorption. In a 2025 study of 15 adults taking a full-spectrum capsule containing both compounds, blood levels of CBDA rose much higher and faster than those of CBD. That suggests CBDA was absorbed more readily from that formulation — a striking contrast with CBD’s main problem — but the study measured blood levels, not health benefits, and it cannot speak for every CBDA product.
Second, CBDA is not just weak CBD — it behaves differently. In cells and animals it has shown effects involving inflammation, nausea, anxiety and seizures, gathered in a 2026 review of the acidic cannabinoids. Those findings explain why researchers and drug companies are interested. They do not show that CBDA treats any of these problems in people. It is also worth knowing that CBDA’s side effects and drug interactions have not been properly mapped.
The first human signals
The human evidence so far is thin and specific. The first treatment signal comes from an open-label study of 11 girls with Rett syndrome, a severe genetic neurological condition. After 12 weeks taking a CBDA-rich extract that also contained CBD, CBGA and a small amount of THC, clinicians and caregivers reported improvements in communication, alertness, eye contact and anxiety. The trial’s blood tests showed CBDA was the main cannabinoid circulating after each dose. Most side effects were mild, but one participant withdrew after a serious allergic reaction.
There was no placebo group, and several researchers worked for the companies funding or developing the product. The study therefore cannot show that the extract caused the improvements — or that CBDA was the ingredient responsible. Rett syndrome has already taught this lesson the hard way: another treatment’s open-label improvements in the same condition disappeared when the placebo-controlled trial was run. We could not find a placebo-controlled trial showing that CBDA treats any health condition.
One more flag, because marketing leans on it: some widely shared “CBDA” findings — on obesity and metabolism in particular — used a chemically modified CBDA derivative designed to resist breakdown. That derivative is a different drug, and its results cannot be transferred to an ordinary CBDA oil.
What users report
CBDA has a devoted user community, and it grew out of raw-cannabis juicing — people blending fresh leaves and buds precisely to get the acids without the high. Among reader accounts and reports shared online, the same descriptions recur: less digestive discomfort, less pain and stiffness, often from people with inflammatory conditions such as Crohn’s disease or arthritis. Others report no effect, or dislike the taste and gut effects of raw oils.
These experiences deserve the weight we give reports everywhere on this site: they are real, consistently told, and they are part of why the compound is being studied. What they cannot show is that CBDA caused the change or that the underlying disease is under control — conditions like Crohn’s naturally flare and settle, and people usually change several things at once. The distinction matters, and a trial makes it concrete: in a controlled trial of CBD-rich cannabis in Crohn’s disease, participants felt better and their quality of life improved, but tests found no significant change in intestinal inflammation. Feeling better matters. It is not necessarily the same as the disease being under control — and someone with Crohn’s should know which one their oil is doing, which is a conversation for their gastroenterologist, not a label.
What about eating raw cannabis?
Juicing raw cannabis usually delivers mostly non-intoxicating cannabinoid acids. However, some THCA may already have converted into THC during drying or storage, so raw cannabis is not guaranteed to be non-intoxicating or drug-test-safe. As therapy, the juicing claims rest on the same animal work as everything above, minus the dose control: nobody knows how much CBDA a glass of juiced leaves delivers, and it varies with the plant, the leaf and the day.
The honest summary
CBDA reaches the blood more readily than CBD in the limited research so far, it behaves differently in the laboratory, and one small open-label study has produced a human signal. But no placebo-controlled trial has shown it treats any condition, and products change as they sit on the shelf. If you buy one, choose a recently tested product whose COA lists CBDA and CBD, store it as directed, and do not pay extra for unproven treatment claims. CBDA’s side effects and drug interactions have not been mapped, so ask a pharmacist or clinician if you take medication. Our guide to the minor cannabinoids covers where CBDA sits among its siblings.
Nothing in this article is medical advice. Rett syndrome families in particular: the extract above was given in a monitored trial — talk to your child’s neurologist, not a dispensary.
